Corifollitropin alfa for poor responders patients, a prospective randomized study

• Asıl Yazarlar: F. M. Fusi (Yazar), L. Zanga (Yazar), M. Arnoldi (Yazar), S. Melis (Yazar), M. Cappato (Yazar), I. Candeloro (Yazar), A. Di Pasqua (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2020-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background Poor ovarian response remains one of the biggest challenges for reproductive endocrinologists. The introduction of corifollitropin alpha (CFA) offered an alternative option to other gonadotropins for its longer half-life, its more rapid achievement of the threshold and higher FSH...